COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Hemab Therapeutics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$32.09+2.02 (+6.72%)
Close on Oct 19, 2026
- Market cap
- $966.27M
- P/E (TTM)
- –
- Dividend yield
- –
About Hemab Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Hemab Therapeutics Holdings, Inc. is listed on Nasdaq under the ticker COAG, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2025.
Company profile
Company
- Legal name
- Hemab Therapeutics Holdings, Inc.
- Headquarters
- Cambridge, MA
- Address
- 101 Main Street, Suite 1220 02142
- Phone
- (452) 138-7627
- Website
- hemab.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- COAG
- Exchange
- Nasdaq
- IPO date
- May 1, 2026
- Shares outstanding
- 47M, Jul 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2114044
- CUSIP
- 423494103
- ISIN
- US4234941031
- EIN
- 41-4241952
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Benny Sorensen | See Remarks, Director | – |
| Catherine Madigan | Chief Medical Officer | – |
| Mads Nikolaj Behrndt-Eriksen | See Remarks | 36,520 |
| Ananthram Sreenivasa Murthy | Chief Operating Officer | – |
| Keli Walbert | Director | – |
| RA Capital Nexus Fund IV, L.P. | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | – |
| John Maraganore | Director | 17,974 |
| Linda Bain | Director | – |
| Laura Tadvalkar | Director | – |
| Akshay Vaishnaw | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 1, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 27, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |